Astellas Pharma Inc. and UMN Pharma Inc.  today announced that the administration of the recombinant seasonal influenza HA vaccine UMN-0502(ASP7374) was successfully completed in new two currently ongoing Phase III clinical trials. Astellas Pharma has been pursuing drug development of this vaccine in cooperation with UMN Pharma.